Drug profile · INN
dinutuximab beta
QARZIBA (PREVIOUSLY DINUTUXIMAB BETA EUSA AND DINUTUXIMAB BETA APEIRON)
dinutuximab beta (QARZIBA (PREVIOUSLY DINUTUXIMAB BETA EUSA AND DINUTUXIMAB BETA APEIRON)) is a disialoganglioside gd2 inhibitor.
EMA: approved Antineoplastic and immunomodulating agents (L01) L01FX06
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — dinutuximab beta
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 1
- Data quality
- 0.83
Quick answer
dinutuximab beta (QARZIBA (PREVIOUSLY DINUTUXIMAB BETA EUSA AND DINUTUXIMAB BETA APEIRON)) is a disialoganglioside gd2 inhibitor.
Key facts
INN dinutuximab beta
Brand QARZIBA (PREVIOUSLY DINUTUXIMAB BETA EUSA AND DINUTUXIMAB BETA APEIRON)
Mechanism Disialoganglioside GD2 inhibitor
Target Disialoganglioside GD2
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01FX06
Mechanism of action
Disialoganglioside GD2 inhibitor
Primary target: Disialoganglioside GD2
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is dinutuximab beta?
dinutuximab beta (QARZIBA (PREVIOUSLY DINUTUXIMAB BETA EUSA AND DINUTUXIMAB BETA APEIRON)) is a disialoganglioside gd2 inhibitor.
What is the brand name for dinutuximab beta?
QARZIBA (PREVIOUSLY DINUTUXIMAB BETA EUSA AND DINUTUXIMAB BETA APEIRON) is a marketed brand name for dinutuximab beta. Check FDA Drugs@FDA for the current US label holder and prescribing information.